Clinical Trials Browser

Breast Neoplasms, Neoplastic Cells, Circulating

NCT05360290 2026-02-03

CTCNeoBC-E

Phase NA Recruiting

484 enrolled

Breast

Breast Neoplasms, Neoplastic Cells, Circulating

NCT02958852 2025-09-10

ABC-SE

Phase 2 Completed

126 enrolled

Breast

Breast Neoplasms, Neoplastic Cells, Circulating

NCT06904625 2025-08-19

CAPT CTC

Phase NA Recruiting

36 enrolled

BreastGenitourinary

Breast Neoplasms, Neoplastic Cells, Circulating, Prostatic Neoplasms

NCT06067503 2025-04-22

Biomarkers to Detect Endocrine Therapy Resistance

Phase 2 Recruiting

8 enrolled

Breast

Breast Neoplasms, Neoplastic Cells, Circulating, Neoplasm Metastasis, Carcinoma, Lobular

NCT06807502 2025-03-11

PROBE-CTC

Phase NA Recruiting

93 enrolled

Breast

Breast Neoplasms, Neoplastic Cells, Circulating, Neoplasm Metastasis

NCT01015625 2024-08-19

POSYTIVE

Phase NA Completed

90 enrolled 16 charts

Breast

Breast Neoplasms, Neoplastic Cells, Circulating

NCT01619111 2024-06-04

DETECT III

Phase 3 Completed

105 enrolled

Breast

Breast Neoplasms, Neoplastic Cells, Circulating

NCT02035813 2024-06-04

DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs).

Phase 2 Completed

116 enrolled

Breast

Breast Neoplasms, Neoplastic Cells, Circulating

NCT03928210 2023-12-13

Digoxin Induced Dissolution of CTC Clusters

Phase EARLY_PHASE1 Completed

58 enrolled

Breast

Breast Neoplasms, Neoplastic Cells, Circulating

NCT04993014 2021-08-06

HER2Cell

Phase 2 Recruiting

80 enrolled

Breast

Breast Neoplasms, Neoplastic Cells, Circulating

NCT01548677 2019-03-13

TREAT-CTC

Phase 2 Completed

1,317 enrolled

Breast

Breast Neoplasms, Neoplastic Cells, Circulating

NCT02941536 2018-12-27

Correlation Between Circulating Tumor Cells and Brain Disease Control After Focal Radiotherapy for Metastases of Breast Cancer

Phase NA Completed

40 enrolled

BreastCNS

Brain Neoplasms, Breast Neoplasms, Neoplastic Cells, Circulating

NCT03070002 2018-11-20

Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor Cells

Phase 2 Terminated

1 enrolled 6 charts

Breast

Breast Neoplasms, Neoplastic Cells, Circulating

NCT01710605 2018-04-09

Medico-economic Interest of Taking Into Account Circulating Tumor Cells (CTC) to Determine the Kind of First Line Treatment for Metastatic, Hormone-receptors Positive, Breast Cancers

Phase 3 Unknown

800 enrolled

Breast

Breast Neoplasms, Neoplastic Cells, Circulating

NCT02602938 2015-11-13

ACABC

Phase 2 Unknown

40 enrolled

BreastGastrointestinal

Breast Neoplasms, Neoplastic Cells, Circulating, Colorectal Neoplasms

NCT00429182 2013-04-10

Purged Circulating Tumor Cells (CTCs) From Metastatic Breast Cancer

Phase 2 Completed

32 enrolled 6 charts

Breast

Breast Neoplasms, Neoplastic Cells, Circulating

Clinical Trials

GALIA

CTCNeoBC-E

ABC-SE

CAPT CTC

Biomarkers to Detect Endocrine Therapy Resistance

PROBE-CTC

POSYTIVE

DETECT III

DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs).

Digoxin Induced Dissolution of CTC Clusters

HER2Cell

TREAT-CTC

Correlation Between Circulating Tumor Cells and Brain Disease Control After Focal Radiotherapy for Metastases of Breast Cancer

Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor Cells

Medico-economic Interest of Taking Into Account Circulating Tumor Cells (CTC) to Determine the Kind of First Line Treatment for Metastatic, Hormone-receptors Positive, Breast Cancers

ACABC

Purged Circulating Tumor Cells (CTCs) From Metastatic Breast Cancer